Erythromycin and its Derivatives; Salts Thereof
Código 294150 (Harmonized System 2012 by 6 digits)
2015: US$498k, International Sales
2023: US$16.2M, International Purchases
In 2015, the states with the most international sales in Erythromycin and its Derivatives; Salts Thereof were Ciudad de México (US$497k).
The states with the most international purchases in 2023 were Ciudad de México (US$9.52M), Jalisco (US$4.73M), and Estado de México (US$1.79M).
In 2015, the main commercial destinations of Erythromycin and its Derivatives; Salts Thereof were Spain (US$406k), Malaysia (US$83.8k), India (US$7.62k), Colombia (US$5), and United States (US$5).
The main commercial origins of Erythromycin and its Derivatives; Salts Thereof in 2023 were China (US$5.85M), India (US$5.66M), Malaysia (US$3.58M), Spain (US$727k), and Indonesia (US$210k).
In the global context, the main exporting countries of Erythromycin and its Derivatives; Salts Thereof in 2022 were China (US$266M), India (US$83.9M), and United States (US$48.2M). In the same year, the main importing countries of Erythromycin and its Derivatives; Salts Thereof were India (US$118M), Japan (US$34.3M), and Croatia (US$25.3M).
Trade Balance of Mexico
#permalink to sectionNet Trade Balance
#permalink to sectionThe visualizations show the net balance of Erythromycin and its Derivatives; Salts Thereof at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
Net International Trade
#permalink to sectionNovember, 2024: US$425k, International Purchases
In November 2024, international sales of Erythromycin and its Derivatives; Salts Thereof were US$0, while international purchases reached US$425k. The above results in a trade balance of -US$425k.
Exchange by Territory
#permalink to sectionInternational Sales
#permalink to sectionCiudad de México: US$497k, State with the Most International Sales (2015)
Spain: US$406k, Main commercial destination (2015)
In 2015, the states with the highest international sales in Erythromycin and its Derivatives; Salts Thereof were Ciudad de México (US$497k).
In 2015, the countries with the most international purchases from Mexico were Spain (US$406k), Malaysia (US$83.8k), India (US$7.62k), Colombia (US$5), and United States (US$5).
International Purchases
#permalink to sectionCiudad de México: US$9.52M, State with the Most International Purchases (2023)
China: US$5.85M, Main Commercial Origin (2023)
In 2023, the states with the highest international in Erythromycin and its Derivatives; Salts Thereof were Ciudad de México (US$9.52M), Jalisco (US$4.73M), and Estado de México (US$1.79M).
The countries with the most international sales to Mexico in 2023 were China (US$5.85M), India (US$5.66M), Malaysia (US$3.58M), Spain (US$727k), and Indonesia (US$210k).
Specialization
#permalink to sectionSpecialization by State
#permalink to sectionThe RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Erythromycin and its Derivatives; Salts Thereof and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Erythromycin and its Derivatives; Salts Thereof. On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
Global Market
#permalink to sectionOrigins and Trade Destinations
#permalink to section- 0%, Mexican share in global exports - 2022
- 2.52%, Mexican share in global imports - 2022
The visualizations show the global market for Erythromycin and its Derivatives; Salts Thereof. In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Erythromycin and its Derivatives; Salts Thereof were China (US$266M), India (US$83.9M), and United States (US$48.2M). In the same year, the main importing countries for Erythromycin and its Derivatives; Salts Thereof were India (US$118M), Japan (US$34.3M), and Croatia (US$25.3M).